koto_feja
Pfizer (NYSE:PFE) and Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY) announced on Thursday that their jointly developed antitumor agent Xtandi reached its secondary goal as part of a combination therapy in a late-stage trial for certain patients with prostate cancer.
Citing topline data